Welcome!

News Feed Item

Global Protein Therapeutics Market Outlook 2018

NEW YORK, Jan. 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Protein based therapies have found a prominent place in the biopharmaceutical industry since the launch of the human insulin product. They have become one of the most effective clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic disorders. The market holds tremendous potential for future growth and it is estimated that by the end of 2018, it may reach the mark of US$ 165 Billion as new products (especially monoclonal antibodies in the advanced clinical phase) may enter the sector.

According to our new research report, "Global Protein Therapeutics Market Outlook 2018", a large number of market players has been developing monoclonal antibodies (mAbs). Our research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.

Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from Asian countries as huge patients' population and increasing disposable incomes may turn out to be a win-win condition for industry participants.

The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.

The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.

At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided alongwith its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Global Protein Therapeutics Market
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2018
3.2.1 Market Segmentation
4. Industry Performance
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2018
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2018
4.2.3 By Application
4.2.4 Key Geographical Markets

4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2018
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2018
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2018
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2018
4.6.3 Key Players and Drugs
4.6.4 Recent Developments

4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2018
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2018
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. Advanced Phase Drugs Analysis
6. Emerging Market Trends
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
7. Key Players
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.4 Sanofi-Aventis
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.8 Pfizer
7.9 Abbott Laboratories
7.10 Novo Nordisk

List of Figures:

Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2012
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2012-2018
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2012
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2018
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2012
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2011 & 2012
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2011 & 2012
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2011 & 2012
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2010-2012
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2012
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global - Share of US in EPO Market (2012)
Figure 4-15: Global - Insulin Market (Billion US$), 2012-2018

Figure 4-16: Global - Number of Diabetic Patients (Million), 2012 & 2030
Figure 4-17: China - Insulin Market (Billion US$), 2012-2018
Figure 4-18: US - Insulin Market (Billion US$), 2012-2018
Figure 4-19: Japan - Insulin Market (Billion US$), 2012-2018
Figure 4-20: Global - Share of Key Players in Insulin Market (2012)
Figure 4-21: Global - Share of Products in Insulin Market (2012)
Figure 4-22: Global - Interferon Market (Billion US$), 2012-2018
Figure 4-23: Global - Share of Alpha and Beta Products in Interferon Market (2012)
Figure 4-24: Global - Interferon Alpha Market (Billion US$), 2010-2012
Figure 4-25: Global - Interferon Beta Market (Billion US$), 2010-2012
Figure 4-26: US - Interferon Market (Billion US$), 2010-2012
Figure 4-27: Japan - Interferon Market (Million US$), 2010-2012
Figure 4-28: Global - Human Growth Hormone Market (Billion US$), 2012-2018
Figure 4-29: Global - Share of Key Players in Human Growth Hormone Market (2012)
Figure 4-30: Global - Blood Clotting Factor Market (Billion US$), 2012-2018
Figure 4-31: Global - Share of Blood Clotting Factor Market by Segment (2012)
Figure 4-32: Global - Share of Key Players in Blood Clotting Factor Market (2012)
Figure 4-33: Global - Follicle Stimulating Hormone Market (Billion US$), 2012-2018
Figure 4-34: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2018

List of Tables:

Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2010-2012
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2010-2012
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2010-2012
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2010-2012
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2010-2012
Table 4-6: China - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-7: US - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-8: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030
Table 4-9: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2010-2012
Table 4-10: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2010-2012
Table 4-11: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2010-2012
Table 4-12: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2010-2012
Table 4-13: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2010-2012
Table 4-14: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics

To order this report: Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
Who are you? How do you introduce yourself? Do you use a name, or do you greet a friend by the last four digits of his social security number? Assuming you don’t, why are we content to associate our identity with 10 random digits assigned by our phone company? Identity is an issue that affects everyone, but as individuals we don’t spend a lot of time thinking about it. In his session at @ThingsExpo, Ben Klang, Founder & President of Mojo Lingo, discussed the impact of technology on identity. Sho...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
In his session at 20th Cloud Expo, Chris Carter, CEO of Approyo, will discuss the basic set up and solution for an SAP solution in the cloud and what it means to the viability of your company. Chris Carter is CEO of Approyo. He works with business around the globe, to assist them in their journey to the usage of Big Data in the forms of Hadoop (Cloudera and Hortonwork's) and SAP HANA. At Approyo, we support firms who are looking for knowledge to grow through current business process, where even ...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
Addteq is one of the top 10 Platinum Atlassian Experts who specialize in DevOps, custom and continuous integration, automation, plugin development, and consulting for midsize and global firms. Addteq firmly believes that automation is essential for successful software releases. Addteq centers its products and services around this fundamentally unique approach to delivering complete software release management solutions. With a combination of Addteq's services and our extensive list of partners,...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...